Your browser doesn't support javascript.
loading
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
Sheehan, Sharon; Harris, Stephanie A; Satti, Iman; Hokey, David A; Dheenadhayalan, Veerabadran; Stockdale, Lisa; Manjaly Thomas, Zita-Rose; Minhinnick, Alice; Wilkie, Morven; Vermaak, Samantha; Meyer, Joel; O'Shea, Matthew K; Pau, Maria Grazia; Versteege, Isabella; Douoguih, Macaya; Hendriks, Jenny; Sadoff, Jerald; Landry, Bernard; Moss, Paul; McShane, Helen.
Afiliação
  • Sheehan S; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Harris SA; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Satti I; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Hokey DA; Aeras Global TB Vaccine Foundation, Rockville, MD, United States of America.
  • Dheenadhayalan V; Aeras Global TB Vaccine Foundation, Rockville, MD, United States of America.
  • Stockdale L; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Manjaly Thomas ZR; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Minhinnick A; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Wilkie M; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Vermaak S; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Meyer J; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • O'Shea MK; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
  • Pau MG; Janssen Infectious Diseases and Vaccines (formerly Crucell), Leiden, The Netherlands.
  • Versteege I; Janssen Infectious Diseases and Vaccines (formerly Crucell), Leiden, The Netherlands.
  • Douoguih M; Janssen Infectious Diseases and Vaccines (formerly Crucell), Leiden, The Netherlands.
  • Hendriks J; Janssen Infectious Diseases and Vaccines (formerly Crucell), Leiden, The Netherlands.
  • Sadoff J; Janssen Infectious Diseases and Vaccines (formerly Crucell), Leiden, The Netherlands.
  • Landry B; Aeras Global TB Vaccine Foundation, Rockville, MD, United States of America.
  • Moss P; School of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom.
  • McShane H; The Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom.
PLoS One ; 10(11): e0141687, 2015.
Article em En | MEDLINE | ID: mdl-26529238
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenoviridae / Imunização Secundária / Vacinas contra a Tuberculose / Mycobacterium bovis / Mycobacterium tuberculosis / Antígenos de Bactérias Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenoviridae / Imunização Secundária / Vacinas contra a Tuberculose / Mycobacterium bovis / Mycobacterium tuberculosis / Antígenos de Bactérias Idioma: En Ano de publicação: 2015 Tipo de documento: Article